Cargando…
Radiotherapy, Chemotherapy and Immunotherapy—Current Practice and Future Perspectives for Recurrent/Metastatic Oral Cavity Squamous Cell Carcinoma
Oral squamous cell carcinoma is the most common malignant epithelial neoplasm affecting the oral cavity. While surgical resection is the cornerstone of a multimodal curative approach, some tumors are deemed recurrent or metastatic (R/M) and often not suitable for curative surgery. This mainly occurs...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818309/ https://www.ncbi.nlm.nih.gov/pubmed/36611391 http://dx.doi.org/10.3390/diagnostics13010099 |
_version_ | 1784864953509871616 |
---|---|
author | Melo-Alvim, Cecília Neves, Maria Eduarda Santos, Jorge Leitão Abrunhosa-Branquinho, André N. Barroso, Tiago Costa, Luís Ribeiro, Leonor |
author_facet | Melo-Alvim, Cecília Neves, Maria Eduarda Santos, Jorge Leitão Abrunhosa-Branquinho, André N. Barroso, Tiago Costa, Luís Ribeiro, Leonor |
author_sort | Melo-Alvim, Cecília |
collection | PubMed |
description | Oral squamous cell carcinoma is the most common malignant epithelial neoplasm affecting the oral cavity. While surgical resection is the cornerstone of a multimodal curative approach, some tumors are deemed recurrent or metastatic (R/M) and often not suitable for curative surgery. This mainly occurs due to the extent of lesions or when surgery is expected to result in poor functional outcomes. Amongst the main non-surgical therapeutic options for oral squamous cell carcinoma are radiotherapy, chemotherapy, molecular targeted agents, and immunotherapy. Depending on the disease setting, these therapeutic approaches can be used isolated or in combination, with distinct efficacy and side effects. All these factors must be considered for treatment decisions within a multidisciplinary approach. The present article reviews the evidence regarding the treatment of patients with R/M oral squamous cell carcinoma. The main goal is to provide an overview of available treatment options and address future therapeutic perspectives. |
format | Online Article Text |
id | pubmed-9818309 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98183092023-01-07 Radiotherapy, Chemotherapy and Immunotherapy—Current Practice and Future Perspectives for Recurrent/Metastatic Oral Cavity Squamous Cell Carcinoma Melo-Alvim, Cecília Neves, Maria Eduarda Santos, Jorge Leitão Abrunhosa-Branquinho, André N. Barroso, Tiago Costa, Luís Ribeiro, Leonor Diagnostics (Basel) Review Oral squamous cell carcinoma is the most common malignant epithelial neoplasm affecting the oral cavity. While surgical resection is the cornerstone of a multimodal curative approach, some tumors are deemed recurrent or metastatic (R/M) and often not suitable for curative surgery. This mainly occurs due to the extent of lesions or when surgery is expected to result in poor functional outcomes. Amongst the main non-surgical therapeutic options for oral squamous cell carcinoma are radiotherapy, chemotherapy, molecular targeted agents, and immunotherapy. Depending on the disease setting, these therapeutic approaches can be used isolated or in combination, with distinct efficacy and side effects. All these factors must be considered for treatment decisions within a multidisciplinary approach. The present article reviews the evidence regarding the treatment of patients with R/M oral squamous cell carcinoma. The main goal is to provide an overview of available treatment options and address future therapeutic perspectives. MDPI 2022-12-29 /pmc/articles/PMC9818309/ /pubmed/36611391 http://dx.doi.org/10.3390/diagnostics13010099 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Melo-Alvim, Cecília Neves, Maria Eduarda Santos, Jorge Leitão Abrunhosa-Branquinho, André N. Barroso, Tiago Costa, Luís Ribeiro, Leonor Radiotherapy, Chemotherapy and Immunotherapy—Current Practice and Future Perspectives for Recurrent/Metastatic Oral Cavity Squamous Cell Carcinoma |
title | Radiotherapy, Chemotherapy and Immunotherapy—Current Practice and Future Perspectives for Recurrent/Metastatic Oral Cavity Squamous Cell Carcinoma |
title_full | Radiotherapy, Chemotherapy and Immunotherapy—Current Practice and Future Perspectives for Recurrent/Metastatic Oral Cavity Squamous Cell Carcinoma |
title_fullStr | Radiotherapy, Chemotherapy and Immunotherapy—Current Practice and Future Perspectives for Recurrent/Metastatic Oral Cavity Squamous Cell Carcinoma |
title_full_unstemmed | Radiotherapy, Chemotherapy and Immunotherapy—Current Practice and Future Perspectives for Recurrent/Metastatic Oral Cavity Squamous Cell Carcinoma |
title_short | Radiotherapy, Chemotherapy and Immunotherapy—Current Practice and Future Perspectives for Recurrent/Metastatic Oral Cavity Squamous Cell Carcinoma |
title_sort | radiotherapy, chemotherapy and immunotherapy—current practice and future perspectives for recurrent/metastatic oral cavity squamous cell carcinoma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818309/ https://www.ncbi.nlm.nih.gov/pubmed/36611391 http://dx.doi.org/10.3390/diagnostics13010099 |
work_keys_str_mv | AT meloalvimcecilia radiotherapychemotherapyandimmunotherapycurrentpracticeandfutureperspectivesforrecurrentmetastaticoralcavitysquamouscellcarcinoma AT nevesmariaeduarda radiotherapychemotherapyandimmunotherapycurrentpracticeandfutureperspectivesforrecurrentmetastaticoralcavitysquamouscellcarcinoma AT santosjorgeleitao radiotherapychemotherapyandimmunotherapycurrentpracticeandfutureperspectivesforrecurrentmetastaticoralcavitysquamouscellcarcinoma AT abrunhosabranquinhoandren radiotherapychemotherapyandimmunotherapycurrentpracticeandfutureperspectivesforrecurrentmetastaticoralcavitysquamouscellcarcinoma AT barrosotiago radiotherapychemotherapyandimmunotherapycurrentpracticeandfutureperspectivesforrecurrentmetastaticoralcavitysquamouscellcarcinoma AT costaluis radiotherapychemotherapyandimmunotherapycurrentpracticeandfutureperspectivesforrecurrentmetastaticoralcavitysquamouscellcarcinoma AT ribeiroleonor radiotherapychemotherapyandimmunotherapycurrentpracticeandfutureperspectivesforrecurrentmetastaticoralcavitysquamouscellcarcinoma |